The Bayer share price jumped by over 3% after the company published encouraging financial results. Is it a good buy?

Bayer AG (ETR: BAYGN) delivered a robust performance in the third quarter of 2025, reporting a 138% surge in core earnings ...

Shares in Germany’s Bayer looked set to close 6% higher Wednesday, following the company’s presentation of its quarterly ...

Germany's Bayer said Wednesday it had set aside more money to deal with long-running legal woes related to weedkillers, even ...

Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.

The latest announcement is out from Bayer ( (DE:BAYN) ).

SALES FORECAST: The German pharmaceutical and agricultural group is expected to post third-quarter sales of 9.69 billion euros ($11.20 billion,) according to median consensus estimates provided by ...

The world’s most widely used weedkiller is confronting legal battles as well as a cat-and-mouse game with nature. But it’s ...

Bayer said on Wednesday that third-quarter adjusted operating income gained 20.8%, citing gains at the Crop Science division and reconciliation effects in accounting.

Bayer recently reported its third-quarter 2025 results, highlighted by a 20.8% increase in adjusted operating income largely driven by its Crop Science division, as well as new late-breaking Phase III ...

Bayer AG posted an improvement in profit, helped by surprising strength at its crop science business and demand for new drugs. Adjusted third-quarter earnings rose to €1.51 billion ($1.75 billion) ...